The company, to be called VitaTech, would leverage public funding to license longevity technologies developed in U.S. universities and support their continued development. The funds would come from research foundations and government grants such as the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR).
Pfizer-Backed VitaDAO Votes on Creating For-Profit Company to Fund Longevity Research
